CR 3465

Drug Profile

CR 3465

Alternative Names: Leukotriene CYS-LT1 - Rottapharm; Leukotriene LTD4 antagonists - Rottapharm

Latest Information Update: 19 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rottapharm
  • Developer Rottapharm Madaus
  • Class Aromatic amino acids; Small molecules
  • Mechanism of Action Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Interstitial cystitis

Most Recent Events

  • 23 Oct 2014 CR 3465 is still in phase I trials for Asthma and Interstitial cystitis in Italy
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
  • 24 Feb 2010 Preclinical trials in Interstitial cystitis in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top